journal article·2013-12

Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers

Rajaletchumy Veloo Kutty, Si-Shen Feng

Biomaterials· Volume 34· Issue 38
Publisher page

Abstract

We developed a system of Cetuximab-conjugated micelles of vitamin E TPGS for targeted delivery of docetaxel as a model anticancer drug for treatment of the triple negative breast cancer (TNBC), which shows no expression of either one of the hormone progesterone receptor (PR), estrogen receptor (ER) and epidermal growth factor receptor 2 (HER2) and is thus more difficult to be treated than the positive breast cancer. Such micelles are of desired particle size, drug loading, drug encapsulation efficiency and drug release profile. Their surface morphology, surface charge and surface chemistry were also characterized. The fibroblast cells (NIH3T3), HER2 overexpressed breast cancer cells (SK-BR-3), ER and PR overexpressed breast cancer cells (MCF7), and TNBC cells of high, moderate and low EGFR expression (MDA MB 468, MDA MB 231 and HCC38) were employed to access in vitro cellular uptake of the coumarin 6 loaded TPGS micelles and cytotoxicity of docetaxel formulated in the micelles. The high IC50 value, which is the drug concentration needed to kill 50% of the cells in a designated period such as 24 h, obtained from Taxotere(®) showed that the TNBC cells are indeed more resistant to the free drug than the positive breast cancer cells. However, the therapeutic effects of docetaxel could be greatly enhanced by the formulation of Cetuximab conjugated TPGS micelles, which demonstrated 205.6 and 223.8 fold higher efficiency than Taxotere(®) for the MDA MB 468 and MDA MB 231 cell lines respectively.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · HER2/EGFR in Cancer Research · Estrogen and related hormone effects

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (56)

Show source-provided references
1. Cancer statistics, 2013
2. The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance10.1016/j.jsbmb.2011.12.005 ↗
3. Endocrine therapy of breast cancer10.1093/annonc/mdf640 ↗
4. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer10.3816/CBC.2004.n.005 ↗
5. Drug therapy: trastuzumab – mechanism of action and use in clinical practice10.1056/NEJMra043186 ↗
6. Recombinant humanized anti-her2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against her2/neu overexpressing human breast cancer xenografts
7. Triple-negative breast cancer10.1056/NEJMra1001389 ↗
8. Targeted therapy for triple-negative breast cancer: where are we?10.1002/ijc.27632 ↗
9. Triple-negative breast cancer: clinical features and patterns of recurrence10.1158/1078-0432.CCR-06-3045 ↗
10. Breast cancer in African-American women: differences in tumor biology from European-American women10.1158/0008-5472.CAN-06-1927 ↗
11. Descriptive analysis of estrogen receptor (ER) negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype – a population-based study from the California cancer registry10.1002/cncr.22618 ↗
12. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies10.1172/JCI45014 ↗
13. Triple-negative/basal-like breast cancer: review10.1080/00313020802563510 ↗
14. Prognostic markers in triple-negative breast cancer10.1002/cncr.22381 ↗
15. Triple negative breast cancer: unmet medical needs10.1007/s10549-010-1293-1 ↗
16. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy10.1111/j.1524-4741.2009.00789.x ↗
17. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy10.1007/s12282-011-0254-9 ↗
18. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and her-2 is associated with local and distant recurrence after breast-conserving therapy10.1200/JCO.2007.14.4287 ↗
19. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer10.1200/JCO.2006.06.5664 ↗
20. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation10.1002/cncr.24094 ↗
21. Estrogen receptor, progesterone receptor, her-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group10.1200/JCO.2007.14.5565 ↗
22. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer10.1200/JCO.2007.14.4147 ↗
23. Triple-negative breast cancer role of specific chemotherapy agents10.1097/PPO.0b013e3181d24ff7 ↗
24. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes10.1158/1078-0432.CCR-06-1109 ↗
25. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer10.1200/JCO.2003.02.063 ↗
26. Targeting triple-negative breast cancer: optimising therapeutic outcomes10.1093/annonc/mds067 ↗
27. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors – a new paradigm for cancer therapy10.1002/cncr.10372 ↗
28. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications
29. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma10.1158/1078-0432.CCR-04-0220 ↗
30. Epidermal growth factor receptor and her2-neu mRNA expression in non-small cell lung cancer is correlated with survival
31. A comprehensive pathway map of epidermal growth factor receptor signaling10.1038/msb4100014 ↗
32. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma10.1038/modpathol.3800528 ↗
33. Nanomedicine: nanoparticles of biodegradable polymers for cancer diagnosis and treatment
34. Chemotherapeutic engineering: vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo10.1016/j.ces.2007.08.006 ↗
35. Nanomedicine for multimodality treatment of cancer10.2217/nnm.12.159 ↗
36. Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI10.1016/j.biomaterials.2011.04.037 ↗
37. Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats10.2217/nnm.11.111 ↗
38. Formulation of docetaxel by folic acid-conjugated d-alpha-tocopheryl polyethylene glycol succinate 2000 (vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy10.1016/j.biomaterials.2011.02.022 ↗
39. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol)10.1016/S0168-3659(02)00025-1 ↗
40. Cetuximab10.1038/nrd1445 ↗
41. Monoclonal-antibody against epidermal growth-factor receptor is internalized without stimulating receptor phosphorylation10.1073/pnas.83.11.3825 ↗
42. Antibody-induced epidermal growth-factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma-cells10.1016/S0021-9258(18)47026-3 ↗
43. Petit · Am J Pathol · 1997 · 151 · 1523
44. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab10.1200/JCO.2006.08.8021 ↗
45. The EGFR as a target for anticancer therapy – focus on cetuximab10.1016/S0959-8049(01)00233-7 ↗
46. Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles10.1016/j.biomaterials.2013.01.009 ↗
47. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel10.2217/nnm.09.17 ↗
48. Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend10.1016/j.biomaterials.2011.11.051 ↗
49. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery10.1016/j.biomaterials.2010.08.053 ↗
50. Conjugation of monoclonal antibodies to super paramagnetic iron oxide nanoparticles for detection of her2/neu antigen on breast cancer cell lines
51. Multifunctional micellar nanomedicine for cancer therapy10.3181/0808-MR-250 ↗
52. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
53. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer10.1016/j.jconrel.2013.01.035 ↗
54. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs10.1016/j.biomaterials.2004.07.050 ↗
55. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis10.1073/pnas.1006507107 ↗
56. Overexpression of kinesins mediates docetaxel resistance in breast cancer cells10.1158/0008-5472.CAN-09-1224 ↗